Butterflies Move Eastward (GSK, SEPR.DL, SNY)

Butterflies Move Eastward

GlaxoSmithKline (NYSE: GSK ) isn't adding a division of lepidoptera, but yesterday it did buy some really expensive glowing green butterflies.

Glaxo inked a deal with Sepracor (Nasdaq: SEPR ) to market the company's sleep aid Lunesta outside North America and Japan. The drug will be called Lunivia in Europe.

Sepracor will receive $20 million up front and could get up to $155 million if all the milestones, like regulatory approvals, are met. When the drug is brought to market, Glaxo will pay Sepracor double-digit royalties that will escalate as product sales increase, as well as compensation for supplying the drug.

The drug is now under review in the EU where Sepracor expects to receive an approval in the second half of 2008. The market in Europe for sleep aids last year was about $500 million, but only about a quarter of insomnia suffers are on medication, so there's certainly room for the market to grow.

If Glaxo can break into that untapped market, the deal would be a shot in the arm financially for the beleaguered drugmaker. Sales of Lunesta increased a pitiful 2.7% year over year last quarter and have been relatively flat for almost two years now. Sales of the drug have slowed in the U.S. because patients switched from Lunesta to recently released generic versions of Sanofi-Aventis' (NYSE: SNY ) Ambien.

Partnering with a big pharmaceutical company for sales outside the U.S. is certainly a good move for Sepracor. It doesn't have the structure to negotiate pricing in countries with nationalized health care, set up worldwide distribution, or manage sales forces in countries around the world. Now, hopefully, it can put those royalty checks to good use developing its pipeline.

Having trouble sleeping? Here's some more Foolishness to help pass the time:

Best Odds in the Universe!
If you're interested in a 98.79% chance at beating the market... and a 70.84% chance at DOUBLING the market's return – Motley Fool Supernova could be just what you're looking for. And get this: We arrived at these odds from 10,000 random back-tested portfolios composed of Motley Fool Co-founder David Gardner's personal stock picks.

It's why David recently handpicked a small team of world-class portfolio managers. You see, he thinks these odds can get even better! And he'd like to prove it to you...

Simply enter your email address. And the answer to the question everybody is asking will be delivered to your inbox!

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.